Swedish Orphan Biovitrum AB SOBI

Morningstar Rating
SEK 427.80 −6.60 (1.52%)
View Full Chart

Company Report

Sobi's Strategic Portfolio Supports Long-Term Growth and Advancing Pipeline

As recently as 2016, Swedish Orphan Biovitrum, or Sobi, was primarily a specialty pharmaceutical firm focused on in-licensing and commercializing therapies in Europe. Since then, successful launches of hemophilia treatments Elocta and Alprolix, along with a series of acquisitions and partnerships, have expanded Sobi's geographic reach into the US and broadened its presence across hematology and immunology.

Price vs Fair Value

SOBI is trading at a LOCK|?t?wRm premium.
Price
SEK 427.80
Fair Value
LOCK|jl
Uncertainty
LOCK|?CDJ!
1-Star Price
LOCK|T.!
5-Star Price
LOCK|m&
Economic Moat
LOCK|F@$&^
Capital Allocation
LOCK|^@GvPz

Bulls Say, Bears Say

Bulls

Sobi's Altuvoct is emerging as the leading next-generation factor VIII therapy in Europe. Continued patient switching from Elocta, combined with geographic expansion, could drive sales materially above current expectations.

Bears

With a growing number of hemophilia A and B competitors, Sobi could have a difficult time winning market share and maintaining pricing.

Trading Information

Previous Close Price
SEK 434.40
Day Range
SEK 425.60–436.20
52-Week Range
SEK 293.60–487.00
Bid/Ask
SEK 427.60 / SEK 427.80
Shares Outstanding
348.00M
Market Cap
SEK 148.88B
Volume/Avg
232,902 / 342,494

Key Statistics

Price/Earnings (Normalized)
23.00
Price/Sales
4.95
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Mid Growth
Total Number of Employees
2,119

Competitors

Valuation

Metric
SOBI
4502
CSL
Price/Earnings (Normalized)
23.0048.2220.09
Price/Book Value
3.571.203.91
Price/Sales
4.951.963.65
Price/Cash Flow
14.9410.9616.30
Price/Earnings
SOBI
4502
CSL

Financial Strength

Metric
SOBI
4502
CSL
Quick Ratio
0.550.540.88
Current Ratio
0.881.142.21
Interest Coverage
2.700.07−8.46
Quick Ratio
SOBI
4502
CSL

Profitability

Metric
SOBI
4502
CSL
Return on Assets (Normalized)
9.37%5.53%8.38%
Return on Equity (Normalized)
17.61%11.34%17.61%
Return on Invested Capital (Normalized)
13.82%7.74%11.10%
Return on Assets
SOBI
4502
CSL

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Merck KGaA ADR
MKKGY
LOCK|H<!L$@yLOCK|@!R!$67B
Teva Pharmaceutical Industries Ltd
TEVA
LOCK|^$RYPQxvLOCK|PjrTQ$46B
Haleon PLC ADR
HLN
LOCK|@tQ<^<FLOCK|&<#$38B
Zoetis Inc Class A
ZTS
LOCK|&Zh<zR<LOCK|@Yn$29B
Viatris Inc
VTRS
LOCK|z>%#mKsLOCK|vG$20B
Elanco Animal Health Inc
ELAN
LOCK|bRDLOCK|#t$11B
Dr Reddy's Laboratories Ltd ADR
RDY
LOCK|PWw^hzLOCK|<S$10B
Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
LOCK|$z$ybBLOCK|$S$7B
Prestige Consumer Healthcare Inc
PBH
LOCK|j^HD%kLOCK|vfXwj$2B
Perrigo Co PLC
PRGO
LOCK|k$zr?Z!LOCK|&M>$2B

Sponsor Center